SG11201708472WA - Crystalline fgfr4 inhibitor compound and uses thereof - Google Patents
Crystalline fgfr4 inhibitor compound and uses thereofInfo
- Publication number
- SG11201708472WA SG11201708472WA SG11201708472WA SG11201708472WA SG11201708472WA SG 11201708472W A SG11201708472W A SG 11201708472WA SG 11201708472W A SG11201708472W A SG 11201708472WA SG 11201708472W A SG11201708472W A SG 11201708472WA SG 11201708472W A SG11201708472W A SG 11201708472WA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline
- inhibitor compound
- fgfr4 inhibitor
- fgfr4
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147313P | 2015-04-14 | 2015-04-14 | |
| PCT/US2016/027334 WO2016168331A1 (en) | 2015-04-14 | 2016-04-13 | Crystalline fgfr4 inhibitor compound and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708472WA true SG11201708472WA (en) | 2017-11-29 |
Family
ID=55806857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810057UA SG10201810057UA (en) | 2015-04-14 | 2016-04-13 | Crystalline fgfr4 inhibitor compound and uses thereof |
| SG11201708472WA SG11201708472WA (en) | 2015-04-14 | 2016-04-13 | Crystalline fgfr4 inhibitor compound and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201810057UA SG10201810057UA (en) | 2015-04-14 | 2016-04-13 | Crystalline fgfr4 inhibitor compound and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10562888B2 (ko) |
| EP (1) | EP3283465B1 (ko) |
| JP (3) | JP6431622B2 (ko) |
| KR (1) | KR102548229B1 (ko) |
| CN (1) | CN107660200B (ko) |
| AU (2) | AU2016248056B2 (ko) |
| CA (1) | CA2982562C (ko) |
| ES (1) | ES2864712T3 (ko) |
| IL (1) | IL254974B (ko) |
| MX (1) | MX2017013248A (ko) |
| RU (1) | RU2763328C2 (ko) |
| SG (2) | SG10201810057UA (ko) |
| WO (1) | WO2016168331A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3283465B1 (en) * | 2015-04-14 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| CN109803684B (zh) * | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| CN109952290B (zh) * | 2016-11-17 | 2022-05-03 | 广东众生药业股份有限公司 | Fgfr4抑制剂及其制备方法和应用 |
| CN109422760B (zh) * | 2017-09-01 | 2022-05-27 | 南京圣和药物研发有限公司 | Fgfr4抑制剂及其应用 |
| BR112020014112A2 (pt) | 2018-01-10 | 2020-12-01 | Eisai R&D Management Co., Ltd. | terapias de combinação para o tratamento de carcinoma hepatocelular |
| JP2023533903A (ja) | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法 |
| US20230172867A1 (en) | 2020-05-15 | 2023-06-08 | Eisai R&D Management Co., Ltd. | A method for treating cancer with an oral dosage form of an fgfr4 inhibitor |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085666C (zh) * | 1994-11-14 | 2002-05-29 | 沃尼尔·朗伯公司 | 用于抑制蛋白质酪氨酸激酶介导的细胞增殖的6－芳基吡啶并[2,3－d]嘧啶和1,5－二氮杂萘 |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2006038112A1 (en) | 2004-10-01 | 2006-04-13 | Warner-Lambert Company Llc | Use of kinase inhibitors to promote neochondrogenesis |
| CA2634047C (en) | 2005-12-21 | 2016-04-12 | Novartis Ag | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US20090062320A1 (en) | 2007-08-28 | 2009-03-05 | Vito Guagnano | Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor |
| ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| SG181850A1 (en) | 2010-01-14 | 2012-08-30 | Univ Yale | Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
| CN102816162B (zh) | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| EP2804630B1 (en) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Methods of using fgf19 modulators |
| JP5343177B1 (ja) | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| AU2014228746B2 (en) | 2013-03-15 | 2018-08-30 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| EA201591137A1 (ru) | 2013-03-15 | 2016-02-29 | Селджен Авиломикс Рисерч, Инк. | Ингибиторы mk2 и их применения |
| CA2917667A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| AR097455A1 (es) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo |
| MY184733A (en) * | 2013-10-18 | 2021-04-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| WO2015061572A1 (en) | 2013-10-25 | 2015-04-30 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| EP3283465B1 (en) * | 2015-04-14 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Crystalline fgfr4 inhibitor compound and uses thereof |
| CN108884097B (zh) | 2016-05-20 | 2021-05-28 | 浙江海正药业股份有限公司 | 嘧啶类衍生物、其制备方法和其在医药上的用途 |
| JP7103952B2 (ja) | 2016-05-20 | 2022-07-20 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | Ｆｇｆｒ４阻害剤、その製造方法及び応用 |
-
2016
- 2016-04-13 EP EP16718153.6A patent/EP3283465B1/en active Active
- 2016-04-13 CN CN201680031173.7A patent/CN107660200B/zh active Active
- 2016-04-13 RU RU2017139246A patent/RU2763328C2/ru active
- 2016-04-13 US US15/566,527 patent/US10562888B2/en active Active
- 2016-04-13 AU AU2016248056A patent/AU2016248056B2/en active Active
- 2016-04-13 ES ES16718153T patent/ES2864712T3/es active Active
- 2016-04-13 JP JP2017553988A patent/JP6431622B2/ja active Active
- 2016-04-13 WO PCT/US2016/027334 patent/WO2016168331A1/en active Application Filing
- 2016-04-13 SG SG10201810057UA patent/SG10201810057UA/en unknown
- 2016-04-13 SG SG11201708472WA patent/SG11201708472WA/en unknown
- 2016-04-13 MX MX2017013248A patent/MX2017013248A/es unknown
- 2016-04-13 CA CA2982562A patent/CA2982562C/en active Active
- 2016-04-13 KR KR1020177032911A patent/KR102548229B1/ko active IP Right Grant
-
2017
- 2017-10-10 IL IL254974A patent/IL254974B/en active IP Right Grant
-
2018
- 2018-08-01 JP JP2018145018A patent/JP2018188465A/ja active Pending
-
2019
- 2019-12-20 US US16/722,838 patent/US11498916B2/en active Active
-
2020
- 2020-10-22 AU AU2020257131A patent/AU2020257131A1/en not_active Abandoned
- 2020-12-14 JP JP2020206482A patent/JP2021050231A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2864712T3 (es) | 2021-10-14 |
| JP2018511635A (ja) | 2018-04-26 |
| EP3283465B1 (en) | 2021-01-06 |
| AU2016248056A1 (en) | 2017-11-02 |
| JP2018188465A (ja) | 2018-11-29 |
| KR20180003559A (ko) | 2018-01-09 |
| CA2982562C (en) | 2023-06-13 |
| US20200317645A1 (en) | 2020-10-08 |
| KR102548229B1 (ko) | 2023-06-27 |
| CN107660200A (zh) | 2018-02-02 |
| RU2017139246A (ru) | 2019-05-14 |
| AU2016248056B2 (en) | 2020-07-23 |
| RU2017139246A3 (ko) | 2019-10-22 |
| CA2982562A1 (en) | 2016-10-20 |
| IL254974B (en) | 2021-06-30 |
| WO2016168331A1 (en) | 2016-10-20 |
| JP6431622B2 (ja) | 2018-11-28 |
| US10562888B2 (en) | 2020-02-18 |
| CN107660200B (zh) | 2022-01-11 |
| EP3283465A1 (en) | 2018-02-21 |
| SG10201810057UA (en) | 2018-12-28 |
| US11498916B2 (en) | 2022-11-15 |
| BR112017022243A2 (pt) | 2018-07-10 |
| JP2021050231A (ja) | 2021-04-01 |
| IL254974A0 (en) | 2017-12-31 |
| AU2020257131A1 (en) | 2020-11-19 |
| US20180093972A1 (en) | 2018-04-05 |
| MX2017013248A (es) | 2018-07-06 |
| RU2763328C2 (ru) | 2021-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255921A1 (zh) | 嘧啶化合物 | |
| IL259560A (en) | Inhibitors of the menin-mll interaction | |
| GB201705971D0 (en) | Inhibitor compounds | |
| IL254974A0 (en) | Crystalline compound of fgfr4 inhibitor and uses thereof | |
| HK1247607A1 (zh) | P62-zz化學抑制劑 | |
| GB201403536D0 (en) | Inhibitor compounds | |
| EP3303324A4 (en) | Novel corrosion inhibitors | |
| GB201513481D0 (en) | Inhibitor compounds | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| ZA201704301B (en) | Microencapsulated nitrification inhibitor compositions | |
| IL248509A0 (en) | Nitrification inhibitor preparation sealed in a capsule | |
| IL258870A (en) | Substituted indazole compounds as rorgammat inhibitors and uses thereof | |
| GB201505658D0 (en) | Inhibitor compounds | |
| GB201612860D0 (en) | Inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| GB2543488B (en) | Corrosion inhibitor | |
| GB201507036D0 (en) | Crystalline enzyme inhibitor compound | |
| EP3258929A4 (en) | FACTOR IXa INHIBITORS | |
| GB201520949D0 (en) | Inhibitors | |
| GB201720145D0 (en) | Inhibitor compounds | |
| GB201708502D0 (en) | Inhibitor compounds | |
| GB201708507D0 (en) | Inhibitor compounds | |
| GB201708510D0 (en) | Inhibitor compounds | |
| GB201705968D0 (en) | Inhibitor compounds | |
| GB201621619D0 (en) | Inhibitor compounds |